Literature DB >> 3496229

MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons.

I Namura, P Douillet, C J Sun, A Pert, R M Cohen, C C Chiueh.   

Abstract

1-Methyl-4-phenylpyridine (MPP+) is an oxidative metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP). MPP+ produced local cell death when injected directly into substantia nigra compacta, locus coeruleus, or dorsal and median raphe nuclei of rats. Corresponding significant decreases in dopamine, serotonin and norepinephrine levels were observed in the terminal areas. These observations indicate that MPP+ is a non-selective neurotoxin which causes lesions not only in dopaminergic neurons but also in noradrenergic and serotonergic systems following intracranial administration. Selective lesioning of these monoaminergic systems could only be achieved by a stereotaxic injection of MPP+ into specific brain regions containing monoamine neurons.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496229     DOI: 10.1016/0014-2999(87)90775-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Astrocytes and therapeutics for Parkinson's disease.

Authors:  Phillip M Rappold; Kim Tieu
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

2.  Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+.

Authors:  C J Sun; J N Johannessen; W Gessner; I Namura; W Singhaniyom; A Brossi; C C Chiueh
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

3.  An in vitro model of 1-methyl-4-phenyl-pyridinium (MPP+) toxicity: incubation of rabbit caudate nucleus slices with MPP+ followed by biochemical and functional analysis.

Authors:  T J Feuerstein; L Hedler; R Jackisch; G Hertting
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

4.  Effects of MPP+ on catecholamine levels in adrenal glands and heart of rats.

Authors:  M Kujacic; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

5.  Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter.

Authors:  P B Clarke; M Reuben
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

6.  Modelling the dopamine and noradrenergic cell loss that occurs in Parkinson's disease and the impact on hippocampal neurogenesis.

Authors:  Charlotte M Ermine; Jordan L Wright; Stefano Frausin; Jessica A Kauhausen; Clare L Parish; Davor Stanic; Lachlan H Thompson
Journal:  Hippocampus       Date:  2018-02-24       Impact factor: 3.899

Review 7.  Physiological and anatomical link between Parkinson-like disease and REM sleep behavior disorder.

Authors:  Yuan-Yang Lai; Jerome M Siegel
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

8.  TFP5 prevents 1-methyl-4-phenyl pyridine ion-induced neurotoxicity in mouse cortical neurons.

Authors:  Qi-Shan Zhang; Yuan-Gao Liao; Zhong Ji; Yong Gu; Hai-Shan Jiang; Zuo-Shan Xie; Su-Yue Pan; Ya-Fang Hu
Journal:  Exp Ther Med       Date:  2016-09-05       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.